# Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema

> **NCT02734407** · PHASE4 · COMPLETED · sponsor: **Retina-Vitreous Associates Medical Group** · enrollment: 9 (actual)

## Conditions studied

- Clinically Significant Diabetic Macular Edema

## Interventions

- **PROCEDURE:** Assigned Intervention
- **DRUG:** aflibercept 2.0 mg

## Key facts

- **NCT ID:** NCT02734407
- **Lead sponsor:** Retina-Vitreous Associates Medical Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-09-27
- **Final completion:** 2017-09-27
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02734407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02734407, "Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02734407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*